Karen T. Tashima

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman, David Chien Lye, David S.C. Hui et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

Schlomo Staszewski, Javier O Morales-Ramirez, Karen T. Tashima et al. · New England Journal of Medicine · 1999 · 1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

Samir K. Gupta, Joseph A. Eustace, Jonathan Winston et al. · Clinical Infectious Diseases · 2005 · 585 citations · Full text

Medicine, Infectious Diseases, Nephrology +12

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals

David B. Clifford, Scott Evans, Yijun Yang et al. · Annals of Internal Medicine · 2005 · 272 citations

Medicine, Neurology, Pharmacology +16